2. Search Result
Search Result
Results for "

serum effect

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

2

Biochemical Assay Reagents

5

Peptides

2

Inhibitory Antibodies

10

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1956
    Human serum albumin
    4 Publications Verification

    HSA

    		 NF-κB NO Synthase Cardiovascular Disease Inflammation/Immunology Cancer
    Human serum albumin (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, NF-κB, and peroxynitrite (ONOO −) in the vascular wall, contributing to the reduction of blood pressure .
    This product is recombinant Human Serum Albumin expressed in a microbial expression system.
    Human serum albumin
  • HY-P1956A
    Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg)

    HSA (Cell culture grade, Endotoxin<0.125 EU/mg)

    		 NF-κB NO Synthase Cardiovascular Disease Inflammation/Immunology
    Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, iNOS, and peroxynitrite (ONOO −) in the vascular wall, contributing to the reduction of blood pressure. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) can be used for in vitro cell culture .
    This product is human serum albumin recombinantly expressed in an Escherichia coli expression system.
    Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg)
  • HY-13402
    Varespladib
    Maximum Cited Publications
    9 Publications Verification

    LY315920

    		 Phospholipase Inflammation/Immunology
    Varespladib (LY315920) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively .
    Varespladib
  • HY-P990688
    Xaluritamig

    AMG-509

    		 CD3 Cancer
    Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 + T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .
    Xaluritamig
  • HY-P4744
    LL-37 amide
    2 Publications Verification

    		 Formyl Peptide Receptor (FPR) Bacterial Infection Cancer
    LL-37 amide is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED99=8.5-8.7 μg/mL). LL-37 amide exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .
    LL-37 amide
  • HY-13995B
    Sevelamer carbonate
    1 Publications Verification

    		 Drug Derivative Metabolic Disease
    Sevelamer carbonate is an orally active and non-calcium-based phosphate binding agent and used for the hyperphosphatemia of chronic kidney disease (CKD)research. Sevelamer carbonate effectively lowers serum phosphorus levels hile having minimal effect on serum calcium or serum chloride levels in vivo. Sevelamer carbonate is considered as an improved, buffered form of sevelamer (HY-13995) .
    Sevelamer carbonate
  • HY-N8487
    7-Methoxyflavone

    		Cytochrome P450 Neurological Disease Inflammation/Immunology Cancer
    7-Methoxyflavone is a flavonoid compound that can be isolated from Zornia brasiliensis. 7-Methoxyflavone can bind to human serum albumin and is an aromatase inhibitor. 7-Methoxyflavone has peripheral analgesic and certain antitumor activities. 7-Methoxyflavone is effective against chemical pain but has no significant effect on thermal pain .
    7-Methoxyflavone
  • HY-19820A
    NSC45586 sodium
    1 Publications Verification

    		 Akt Ser/Thr Protease Apoptosis MMP Cardiovascular Disease Neurological Disease Inflammation/Immunology
    NSC45586 sodium is an inhibitor of PHLPP. NSC45586 sodium targets the PP2C phosphatase domains of PHLPP1 and PHLPP2, blocks the phosphatase activity of PHLPP, increases the expression level of FOXO1 in the nucleus, and reduces the protein expression of PHLPP1. NSC45586 sodium activates the AKT survival signaling pathway, enhances IGF-1-induced AKT activation, and inhibits the phosphorylation of AKT/ERK under basal conditions. NSC45586 sodium reduces staurosporine-induced neuronal death, preserves notochord cell morphology and KRT19 expression, inhibits cell apoptosis (apoptosis), improves the viability and proliferation of nucleus pulposus cells, upregulates the expression of ACAN/SOX9, and downregulates the expression of MMP13. NSC45586 sodium binds tightly to bovine serum albumin (bovine serum albumin), and exerts a more significant effect on nucleus pulposus in male individuals. NSC45586 sodium can be used in studies related to global cerebral ischemia and intervertebral disc degeneration .
    NSC45586 sodium
  • HY-N0500
    Mogroside III

    		Glycosidase Autophagy Metabolic Disease Endocrinology
    Mogroside III is a triterpenoid glycoside. Mogroside III exhibits maltase inhibitory effect with an IC50 value of 1.6 mM. Mogroside III enhances oocyte developmental potential by promoting autophagy in cumulus cells. Mogroside III, as the active ingredient of the low-polarity glycoside component (L-SGgly), L-SGgly can increase serum GLP-1 levels, improve insulin resistance, and reduce IL-6 levels, and has hypoglycemic, lipid-regulating and anti-inflammatory effects. Mogroside III can be used for the studies of type 2 diabetes mellitus (T2DM) and assisted reproductive technology .
    Mogroside III
  • HY-13402A
    Varespladib sodium
    Maximum Cited Publications
    9 Publications Verification

    LY315920 sodium

    		 Phospholipase Inflammation/Immunology
    Varespladib sodium (LY315920 sodium) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib sodium exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively .
    Varespladib sodium
  • HY-N7912
    Pterosin A

    (2S)-Pterosin A

    		 AMPK PEPCK GSK-3 GLUT Akt p38 MAPK Reactive Oxygen Species (ROS) Metabolic Disease
    Pterosin A ((2S)-Pterosin A) is a sesquiterpene compound. Pterosin A is an orally active AMPK activator with anti-diabetic effect. Pterosin A can promote glucose uptake, increase serum insulin, and improve hyperglycemia and glucose intolerance. Pterosin A can prevent insulin-secreting cells death and reduce ROS production. Pterosin A can be used for the research of metabolic disease, such as diabetes .
    Pterosin A
  • HY-N12540
    Monogalactosyldiacylglycerol

    MGDG

    		 DNA/RNA Synthesis Apoptosis Others
    Monogalactosyldiacylglycerol (MGDG) is a galactolipid with anti-inflammatory and anticancer activities, which is found in photosynthetic organisms. Monogalactosyldiacylglycerol is a potent DNA polymerase inhibitor with pro-apoptotic activity. Monogalactosyldiacylglycerol inhibits the synthesis of LPS (HY-D1056)-induced inflammation-related proteins (Ex-FABP, Avidin, Serum Amyloid A). Monogalactosyldiacylglycerol exerts an anti-proliferative effect on chicken articular chondrocytes . Monogalactosyldiacylglycerol can be used in research related to osteoarthritis, cancer and inflammatory diseases .
    Monogalactosyldiacylglycerol
  • HY-P4744A
    LL-37 amide TFA
    2 Publications Verification

    		 Formyl Peptide Receptor (FPR) Bacterial Infection Cancer
    LL-37 amide TFA is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED99=8.5-8.7 μg/mL). LL-37 amide TFA exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide TFA possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .
    LL-37 amide TFA
  • HY-N2452
    Cochinchinenin C

    		GLP Receptor Cardiovascular Disease Infection Metabolic Disease
    Cochinchinenin C is a GLP-1R agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions .
    Cochinchinenin C
  • HY-P5641
    Pleurocidin
    1 Publications Verification

    		 Bacterial p38 MAPK NF-κB NADH Dehydrogenase Antibiotic Infection Inflammation/Immunology
    Pleurocidin is an Antimicrobial peptide. Pleurocidin is derived from the skin mucosa or intestinal secretions of Pseudopleuronectes americanus. Pleurocidin inhibits the expression of key proteins in the MAPK and NF-κB inflammatory signaling pathways. Pleurocidin alters serum inflammatory and immune cytokine levels, regulates the down-regulation of tight junction proteins, and modulates the intestinal flora. Pleurocidin exerts antibacterial activity by inducing bacterial membrane damage, hydroxyl radical formation, and NADH depletion, and also produces a synergistic effect with Antibiotics. Pleurocidin alleviates DSS-induced ulcerative colitis. Pleurocidin can be used for research on ulcerative colitis, bacterial infections, and bacterial biofilm-related infections .
    Pleurocidin
  • HY-B1226
    Diperodon hydrochloride

    		Histone Methyltransferase Neurological Disease
    Diperodon hydrochloride exerts its effect by being broken down by serum degradoses.
    Diperodon hydrochloride
  • HY-145649A
    Zilebesiran sodium

    AD-85481 sodium; ALN-AGT sodium

    		 Small Interfering RNA (siRNA) Asialoglycoprotein Receptor (ASGPR) Cardiovascular Disease
    Zilebesiran (AD-85481; ALN-AGT) sodium is a long-acting liver-targeted small interfering RNA (siRNA) antihypertensive agent. Zilebesiran sodium binds to the hepatic asialoglycoprotein receptor (ASGPR), activates the RNA-induced silencing complex to degrade hepatic angiotensinogen mRNA, thereby inhibiting the gene expression and synthesis of angiotensinogen. Zilebesiran sodium dose-dependently reduces serum angiotensinogen levels and 24-hour ambulatory blood pressure, with its effect persisting throughout the circadian cycle. Zilebesiran sodium is applicable to research related to hypertension .
    Zilebesiran sodium
  • HY-13402S
    Varespladib-d7

    LY315920-d7

    		 Isotope-Labeled Compounds Phospholipase Inflammation/Immunology
    Varespladib-d7 (LY315920-d7) is a deuterated labeled Varespladib (HY-13402). Varespladib is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively .
    Varespladib-d7
  • HY-N14518
    Pacidamycin 6

    		Bacterial Infection
    Pacidamycin 6 has inhibitory effect on Pseudomonas aeruginosa. Pacidamycin 6 also has effect on a few strains of bacteria such as suppurative staphylococcus and Escherichia coli. Serum can reduce its antibacterial activity, pH also affects its antibacterial activity .
    Pacidamycin 6
  • HY-N14517
    Pacidamycin 4

    		Bacterial Infection
    Pacidamycin 4 has inhibitory effect on Pseudomonas aeruginosa. Pacidamycin 4 also has effect on a few strains of bacteria such as suppurative staphylococcus and Escherichia coli. Serum can reduce its antibacterial activity, pH also affects its antibacterial activity .
    Pacidamycin 4
  • HY-N14519
    Pacidamycin 7

    		Bacterial Infection
    Pacidamycin 7 has inhibitory effect on Pseudomonas aeruginosa. Pacidamycin 7 also has effect on a few strains of bacteria such as suppurative staphylococcus and Escherichia coli. Serum can reduce its antibacterial activity, pH also affects its antibacterial activity .
    Pacidamycin 7
  • HY-118364
    AGN 190727

    		RAR/RXR Metabolic Disease
    AGN 190727 is a structural isomer of AGN 190121 and has no activating effect on RAR/RXR. AGN 190121 is a RAR-specific agonist that causes a dose-dependent increase in serum triglycerides, leading to hypertriglyceridemia.
    AGN 190727
  • HY-N11551
    Salvifaricin

    		Others Others Metabolic Disease
    Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .
    Salvifaricin
  • HY-177378
    HBV-IN-53

    		HBV DNA/RNA Synthesis Infection
    HBV-IN-53 (Compound 1) is an HBV inhibitor. HBV-IN-53 reduces the level of HBV DNA in serum. The inhibitory activity of HBV-IN-53 in combination with Tenofovir disoproxil fumarate (HY-13782) exhibits an additive effect on HBV inhibition .
    HBV-IN-53
  • HY-14998
    Halofenate

    MK 185

    		 β-catenin PPAR Wnt Endocrinology
    Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo .
    Halofenate
  • HY-P1474
    β-Amyloid (22-35)

    Amyloid β-Protein (22-35)

    		 Amyloid-β Neurological Disease
    β-Amyloid 22-35 (Amyloid β-Protein 22-35), the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
    β-Amyloid (22-35)
  • HY-P1474A
    β-Amyloid (22-35) TFA

    Amyloid β-Protein (22-35) TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid 22-35 (Amyloid β-Protein 22-35) TFA, the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 TFA forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
    β-Amyloid (22-35) TFA
  • HY-164526
    SH1573

    		Isocitrate Dehydrogenase (IDH) Cancer
    SH1573 is an orally active mIDH2 inhibitor. SH1573 has a strong and selective inhibitory effect on mIDH2 R140Q protein (IC50=4.78 nmol/L), and can effectively reduce the production of the carcinogenic metabolite 2-hydroxyglutarate (2-HG) in animal models, cell lines, serum and tumors. SH1573 can be used for the study of acute myeloid leukemia (AML) .
    SH1573
  • HY-13402R
    Varespladib (Standard)

    LY315920 (Standard)

    		 Phospholipase Reference Standards Inflammation/Immunology
    Varespladib (Standard) is the analytical standard of Varespladib. This product is intended for research and analytical applications. Varespladib (LY315920) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively .
    Varespladib (Standard)
  • HY-13402AR
    Varespladib sodium (Standard)

    LY315920 sodium (Standard)

    		 Phospholipase Reference Standards Inflammation/Immunology
    Varespladib (sodium) (Standard) is the analytical standard of Varespladib (sodium). This product is intended for research and analytical applications. Varespladib sodium (LY315920 sodium) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib sodium exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively .
    Varespladib sodium (Standard)
  • HY-168340
    COX-2/15-LOX-IN-6

    		COX Lipoxygenase Inflammation/Immunology
    COX-2/15-LOX-IN-6 (Compound 5l) is the dual inhibitor for COX-2 and 15-LOX, with IC50 of 0.201 μM and 11.723 μM. COX-2/15-LOX-IN-6 inhibits the expression of PGE, TNF-α, IL-6 and iNOS in serum, and exhibits anti-inflammatory effect in Carrageenan (HY-125474)-induced rats edema model .
    COX-2/15-LOX-IN-6
  • HY-176466
    ST-899

    		Platelet-activating Factor Receptor (PAFR) TNF Receptor Inflammation/Immunology
    ST-899 is a novel platelet-activating factor (PAF) receptor antagonist. ST-899 can significantly reduce the mortality of mice with endotoxin (LPS)-induced shock. ST-899 can significantly inhibit the increase in serum tumor necrosis factor (TNF) levels induced by LPS, but has no effect on interleukin-6 (IL-6). The regulatory mechanism of ST-899 is to block the positive feedback loop between PAF and TNF, thereby reducing the inflammatory response. ST-899 can be used to study inflammatory diseases such as septic shock .
    ST-899
  • HY-121413
    Clinolamide

    		Endogenous Metabolite Others
    Clinolamide is an N-cyclohexyl linoleamide. In a rat cholesterol metabolism study, feeding it at a dose of 0.3% for 21 days had no significant effect on serum, liver or kidney cholesterol levels, but had different effects on cholesterol synthesis in liver slices under different substrates and concentrations.
    Clinolamide
  • HY-182543
    NPS-467

    		CaSR Others
    NPS-467 is a calcium-sensing receptor (CaR) activator and stereospecific agent with only its R-enantiomer active. NPS-467 increases the sensitivity of the CaR to activation by extracellular calcium. NPS-467 stimulates stanniocalcin (STC) secretion in trout and induces inhibition of gill calcium transport in trout. NPS-467 has no effect on serum calcitonin levels in trout .
    NPS-467
  • HY-W343043
    Pyrazinoylguanidine

    PZG

    		 Drug Derivative Cardiovascular Disease Metabolic Disease
    Pyrazinoylguanidine (PZG) is an analogue of the potassium sparing diuretic, Amiloride (HY-B0285). Pyrazinoylguanidine can lower the systolic and diastolic blood pressure of patients with primary hypertension, has a certain effect on reducing heart rate, and does not affect the concentrations of electrolytes such as sodium, potassium, and chloride in the blood serum. Pyrazinoylguanidine can reduce the hyperglycemia and hyperinsulinemia in type 2 diabetes, reduce the levels of triglycerides, cholesterol, and free fatty acids, and reverse the hyperglycemia and hyperlipidemia induced by thiazide diuretics, such as Hydrochlorothiazide (HY-B0252). Pyrazinoylguanidine ican nhibit the reabsorption of urea by the renal tubules, thereby increasing the clearance rate and excretion volume of urea, reducing the serum urea concentration, and minimizing its toxic accumulation .
    Pyrazinoylguanidine
  • HY-N8487R
    7-Methoxyflavone (Standard)

    		Reference Standards Cytochrome P450 Neurological Disease Inflammation/Immunology Cancer
    7-Methoxyflavone (Standard) is the analytical standard of 7-Methoxyflavone (HY-N8487). This product is intended for research and analytical applications. 7-Methoxyflavone is a flavonoid compound that can be isolated from Zornia brasiliensis. 7-Methoxyflavone can bind to human serum albumin and is an aromatase inhibitor. 7-Methoxyflavone has peripheral analgesic and certain antitumor activities. 7-Methoxyflavone is effective against chemical pain but has no significant effect on thermal pain .
    7-Methoxyflavone (Standard)
  • HY-181161
    AChE-IN-107

    		Cholinesterase (ChE) Neurological Disease
    AChE-IN-107 is a selective acetylcholinesterase (AChE) inhibitor with an IC50 of 0.22 μM and a Ki of 0.207 μM. AChE-IN-107 shows no inhibitory effect on equine serum BChE at 10 μM. AChE-IN-107 exhibits mixed-type inhibition of electric eel acetylcholinesterase, binding to both free enzyme and enzyme-substrate complex. AChE-IN-107 acts as a cytotoxin, reduces cell viability in hepatocellular carcinoma HepG2 cells.AChE-IN-107 can be used for the research of alzheimer's disease .
    AChE-IN-107
  • HY-139792
    Besigliptin tosylate

    SHR117887

    		 Endogenous Metabolite Metabolic Disease
    Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .
    Besigliptin tosylate
  • HY-19215
    U-96988

    PNU-96988

    		 HIV HIV Protease Infection
    U-96988 (PNU-96988) is a non-peptide HIV-1 protease inhibitor with a Ki value of 38 nM. U-96988 is also effective against HIV-2 protease. U-96988 exhibits an IC50 for HIV-1IIIB of 5 μM. U-96988 can be used for research on HIV infection .
    U-96988
  • HY-178355
    Anti-osteoporosis agent-12

    		Drug Derivative Metabolic Disease
    Anti-osteoporosis agent-12 (Compound 18) is an orally active pyrazole-fused betulinic acid derivative with potent anti-osteoporosis activity. Anti-osteoporosis agent-12 exhibits a strong inhibitory effect on RANKL-induced osteoclastogenesis in RAW264.7 cells, with an IC50 of 7.96 nM. Anti-osteoporosis agent-12 can dose-dependently improve key micro-CT parameters of bone, reduce the level of serum bone resorption marker (CTx), and effectively prevent ovariectomy-induced bone loss. Anti-osteoporosis agent can be used for the study of osteoporosis .
    Anti-osteoporosis agent-12
  • HY-W968308
    H-Gly-D-Ala-OH

    		Amino Acid Derivatives Metabolic Disease
    H-Gly-D-Ala-OH is a dipeptide containing D-amino acid. H-Gly-D-Ala-OH can be specifically hydrolyzed by renal dipeptidase, which acts on peptide segments with a D-amino acid at the carboxyl terminus. H-Gly-D-Ala-OH enables highly specific detection of renal dipeptidase activity without interference from other serum or urine aminopeptidases. When used in combination with low-dose Sodium nitrite (HY-N11218), H-Gly-D-Ala-OH inhibits the initial spore growth of Clostridium botulinum in pork homogenate, whereas it has no such effect on its own. H-Gly-D-Ala-OH can be used in research related to chronic renal failure, diabetes mellitus and botulism .
    H-Gly-D-Ala-OH

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: